Cyclacel Pharmaceuticals Net Income
| CYCCDelisted Stock | USD 6.37 0.39 5.77% |
Cyclacel Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cyclacel Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cyclacel Pharmaceuticals' valuation are provided below:Cyclacel Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cyclacel |
Search Suggestions
| CY | Cypress Semiconductor | CompanyDelisted |
| CYD | China Yuchai International | Company |
| CYBAX | Calvert High Yield | Mutual Fund |
| CYA | Simplify Asset Management | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Cyclacel Pharmaceuticals reported net income of (11.21 Million). This is 103.29% lower than that of the Biotechnology sector and 116.01% lower than that of the Health Care industry. The net income for all United States stocks is 101.96% higher than that of the company.
Cyclacel Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclacel Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclacel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics of similar companies.Cyclacel Pharmaceuticals is currently under evaluation in net income category among its peers.
Cyclacel Fundamentals
| Return On Equity | -2.77 | |||
| Return On Asset | -1.03 | |||
| Current Valuation | 10.9 M | |||
| Shares Outstanding | 2.24 M | |||
| Shares Owned By Insiders | 80.14 % | |||
| Shares Owned By Institutions | 0.79 % | |||
| Number Of Shares Shorted | 96.28 K | |||
| Price To Earning | (0.40) X | |||
| Price To Book | 4.18 X | |||
| Price To Sales | 1,516 X | |||
| Revenue | 43 K | |||
| Gross Profit | 10 K | |||
| EBITDA | (12 M) | |||
| Net Income | (11.21 M) | |||
| Cash And Equivalents | 29.08 M | |||
| Cash Per Share | 2.32 X | |||
| Total Debt | 6.27 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.38 X | |||
| Book Value Per Share | 2.29 X | |||
| Cash Flow From Operations | (7.99 M) | |||
| Short Ratio | 0.01 X | |||
| Earnings Per Share | 7,124 X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 10 | |||
| Beta | 0.16 | |||
| Market Capitalization | 15.16 M | |||
| Total Asset | 4.09 M | |||
| Retained Earnings | (439.49 M) | |||
| Working Capital | (2.59 M) | |||
| Current Asset | 24.57 M | |||
| Current Liabilities | 5.75 M | |||
| Annual Yield | 0.49 % | |||
| Net Asset | 4.09 M |
About Cyclacel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclacel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclacel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Cyclacel Stock
If you are still planning to invest in Cyclacel Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclacel Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |